Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Gets What It Wants – Allergan Generics, Not Mylan

This article was originally published in The Tan Sheet

Executive Summary

Teva’s $40.5 billion acquisition of Allergan Generics will solidify Teva as the world’s leading generics company with $26 billion in combined revenues and 320 ANDAs pending at FDA.

You may also be interested in...



Pharma Dealmaker Saunders Includes Wellness Space In Acquisition Group’s Investment Targets

Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.

Stockwatch: Teva, Mylan And The Pandemic – Should Have Done Better

The notoriously thin margins of generic drug manufacturers, over-leveraging and pending legal cases should have been subordinated by the continuing needs for generic drugs during lockdowns.

Upjohn/Mylan: Will "Potential Moderate Growth" Lure Investors?

The combined company will have pro forma 2020 revenues of $19bn to $20bn, generate $1bn in synergies by 2023 and be led by Upjohn CEO Michael Goettler. Mylan's longtime CEO Heather Bresch will depart.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel